Breaking News


Efficacy and safety of etanercept in children and adolescents with severe plaque psoriasis


A post-hoc analysis of a double-blind, placebo-controlled study (12-week double-blind, 24-week open-label) evaluated the efficacy and safety of etanercept (0.8 mg/ week s.c.) in 192 children aged 8-17 years with severe plaque psoriasis. The primary efficacy measure was a 75% or greater improvement in the Psoriasis Area and Severity Index (PASI 75) score from baseline at week 12. Secondary efficacy variables included PASI 50, PASI 75 and PASI 90 responses at weeks 24 and 36 and static Physician Global Assessment (sPGA) of "clear/almost clear" at weeks 12 and 36. PASI 75 was attained by 54.7 and 11.3% of etanercept and placebo recipients, respectively at week 12 (P < 0.001). PASI 50, ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list